Porphyria: Difference between revisions

No edit summary
No edit summary
Line 1: Line 1:
==Background==
==Background==
*Related to defect(s) in heme synthesis causing a buildup of porphyrins
*Autosomal dominant, but poor penetrance
* Inherited and/or acquired disorders of in which there are enzyme deficiencies involved in heme biosynthesis.  
* Inherited and/or acquired disorders of in which there are enzyme deficiencies involved in heme biosynthesis.  
* Heme is a component of many essential hemoproteins, such as hemoglobin, myoglobin and cytochromes, including the cytochrome P450 enzymes
* Heme is a component of many essential hemoproteins, such as hemoglobin, myoglobin and cytochromes, including the cytochrome P450 enzymes
Line 5: Line 7:
* The enzyme deficiencies in porphyria limit the capacity of the liver to increase heme synthesis.  
* The enzyme deficiencies in porphyria limit the capacity of the liver to increase heme synthesis.  
* When drugs, hormones or other factors that induce ALAS and CYPs are given, ALA and porphobilinogen (PBG) are overproduced and accumulate, and a neurovisceral attack may develop
* When drugs, hormones or other factors that induce ALAS and CYPs are given, ALA and porphobilinogen (PBG) are overproduced and accumulate, and a neurovisceral attack may develop
===Triggers===
*Infection, metabolic stress
*Carbohydrate deficiency
*Tobacco, EtOH
*Porphyrinogenic drugs: sulfonamides, barbiturates, rifampin or metoclopramide


==Clinical Features==
==Clinical Features==
*History of porphyrinogenic drugs: sulfonamides, barbiturates, rifampin or metoclopramide
*Gastrointestinal symptoms
*Gastrointestinal symptoms
**Acute [[abdominal pain]] (85-90% of attacks)
**Acute [[abdominal pain]] (85-90% of attacks)
Line 28: Line 35:
==Diagnosis==
==Diagnosis==
''Consider porphyria in patients with abdominal pain that is unexplained after an initial workup has excluded common causes (appendicitis, cholecystitis, pancreatitis, etc).''
''Consider porphyria in patients with abdominal pain that is unexplained after an initial workup has excluded common causes (appendicitis, cholecystitis, pancreatitis, etc).''
 
* Spot urinary porphobilinogen (sendout at most hospitals)
* Urinary porphobilinogen  
**Normal = 0-4 mg/day
**Normal = 0-4 mg/day
**acute attack, spot urine can be 20-200 mg/L
**acute attack, spot urine can be 20-200 mg/L
Line 35: Line 41:


==Management==
==Management==
*Analgesia
*Avoid offending meds
**Most seizure meds contraindicated: [[Benzodiazepines]], [[gabapentin]], [[levetiracetam]], and [[vigabatrin]] okay
**Avoid [[reglan]]
*Glucose load
**Decreases porphyrin production
**Typical protocol is D10W 3-4 liters daily x 4 days
**Risk of hyponatremia given significant free water load
*Hemin
**Decreases porphyrin production, significantly more potent than glucose
**Recommended for most cases requiring hospitalization, or any with neurologic symptoms
**3-4 mg/kg daily for 4 days
**Can cause significant infusion site phlebitis - minimize by reconstituting in 25% albumin; consider central venous administration
**Very expensive - around $8000 per 313 mg vial
*Hemin (Panhematin®) 3-4 mg/kg IV daily x 4 days
*Hemin (Panhematin®) 3-4 mg/kg IV daily x 4 days
**If the diagnosis is confirmed, the first dose can be given in the ED
**If the diagnosis is confirmed, the first dose can be given in the ED
Line 54: Line 75:


==External Links==
==External Links==
http://www.porphyriafoundation.com/


==References==
==References==
Line 59: Line 81:
# Anderson KE, Bloomer, JR Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR and Desnick RJ. Recommendations for the Diagnosis and Treatment of the Acute Porphyrias. Ann Intern Med 2005; 142:439-450
# Anderson KE, Bloomer, JR Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR and Desnick RJ. Recommendations for the Diagnosis and Treatment of the Acute Porphyrias. Ann Intern Med 2005; 142:439-450
# Deacon AC, Peters TJ, Identification of acute porphyria: evaluation of a commercial screening test for urinary porphobilinogen. Ann Clin Biochem. 1998;35:726-32
# Deacon AC, Peters TJ, Identification of acute porphyria: evaluation of a commercial screening test for urinary porphobilinogen. Ann Clin Biochem. 1998;35:726-32
[[Category:Heme/Onc]]
==Background==
*Related to defect(s) in heme synthesis causing a buildup of porphyrins
*Autosomal dominant, but poor penetrance
==Clinical Features==
*Hallmark is abdominal pain with otherwise negative workup
*May develop neurological symptoms - paresthesias, weakness. May progress to bulbar involvement and need for respiratory support/intubation.
==Triggers==
*Infection, metabolic stress
*Carbohydrate deficiency
*Tobacco, EtOH
==Diagnosis==
*Unlikely to diagnose first episode in ED given rarity of disease
*Can check spot urine porphobilinogen (PBG) - sendout at most hospitals
==Management==
*Analgesia
*Avoid offending meds
**Most seizure meds contraindicated. [[Benzodiazepines]], [[gabapentin]], [[levetiracetam]], and [[vigabatrin]] OK
**Avoid [[reglan]]
*Glucose load
**Decreases porphyrin production
**Typical protocol is D10W 3-4 liters daily x 4 days
**Risk of hyponatremia given significant free water load
*Hemin
**Decreases porphyrin production, significantly more potent than glucose
**Recommended for most cases requiring hospitalization, or any with neurologic symptoms
**3-4 mg/kg daily for 4 days
**Can cause significant infusion site phlebitis - minimize by reconstituting in 25% albumin; consider central venous administration
**Very expensive - around $8000 per 313 mg vial
==Disposition==
*Admit all but very minor attacks
==See Also==
==External Links==
http://www.porphyriafoundation.com/
==References==
<references/>
<references/>


[[Category:Heme/Onc]]
[[Category:Heme/Onc]]

Revision as of 12:24, 11 May 2016

Background

  • Related to defect(s) in heme synthesis causing a buildup of porphyrins
  • Autosomal dominant, but poor penetrance
  • Inherited and/or acquired disorders of in which there are enzyme deficiencies involved in heme biosynthesis.
  • Heme is a component of many essential hemoproteins, such as hemoglobin, myoglobin and cytochromes, including the cytochrome P450 enzymes
  • The first enzyme in the heme production pathway is ALA synthase (ALAS), which controls the rate of heme synthesis in the liver. This enzyme is down-regulated by heme.
  • The enzyme deficiencies in porphyria limit the capacity of the liver to increase heme synthesis.
  • When drugs, hormones or other factors that induce ALAS and CYPs are given, ALA and porphobilinogen (PBG) are overproduced and accumulate, and a neurovisceral attack may develop

Triggers

  • Infection, metabolic stress
  • Carbohydrate deficiency
  • Tobacco, EtOH
  • Porphyrinogenic drugs: sulfonamides, barbiturates, rifampin or metoclopramide

Clinical Features

  • Gastrointestinal symptoms
  • Neurologic symptoms
    • Diffuse musculoskeletal pain
    • headache
    • Sensory loss (40%)
      • An indication of a severe and potentially life-threatening attack
      • Neuropathy can progress to respiratory failure in hours or days
    • Bladder paresis
    • Agitation, confusion, combativeness, seizure

Differential Diagnosis

Diffuse Abdominal pain

Extra-abdominal Sources of Abdominal pain

Diagnosis

Consider porphyria in patients with abdominal pain that is unexplained after an initial workup has excluded common causes (appendicitis, cholecystitis, pancreatitis, etc).

  • Spot urinary porphobilinogen (sendout at most hospitals)
    • Normal = 0-4 mg/day
    • acute attack, spot urine can be 20-200 mg/L
  • Recurrent attacks in a patient with proven acute porphyria are usually similar and can be diagnosed on clinical grounds without biochemical reconfirmation.

Management

  • Analgesia
  • Avoid offending meds
  • Glucose load
    • Decreases porphyrin production
    • Typical protocol is D10W 3-4 liters daily x 4 days
    • Risk of hyponatremia given significant free water load
  • Hemin
    • Decreases porphyrin production, significantly more potent than glucose
    • Recommended for most cases requiring hospitalization, or any with neurologic symptoms
    • 3-4 mg/kg daily for 4 days
    • Can cause significant infusion site phlebitis - minimize by reconstituting in 25% albumin; consider central venous administration
    • Very expensive - around $8000 per 313 mg vial
  • Hemin (Panhematin®) 3-4 mg/kg IV daily x 4 days
    • If the diagnosis is confirmed, the first dose can be given in the ED
  • Glucose loading
    • Has a similar effect, but is much less potent and effective and should be used only for mild attacks.
  • Discontinue any inciting drugs
  • Treat any electrolyte abnormalities
  • Treat pain with narcotic analgesia and nausea with phenothiazines
  • beta blockers can be used to treat tachycardia
  • Seizures should be treated with gabapentin, benzodiazepines and vigabatrin.
    • Patients who have a seizure during an acute porphyria attack rarely need long term anticonvulsant therapy.

Disposition

  • Admission to a monitored bed

See Also

External Links

http://www.porphyriafoundation.com/

References

  1. NR Pimstone, KE. Anderson, B Freilich. (n.d.). Emergency Room Guidelines for Acute Porphyria. American Porphyria Foundation. Retrieved January 11, 2016. From http://www.porphyriafoundation.com/for-healthcare-professionals/emergency-guidelines-for-acute-porphyria#Treatment.
  2. Anderson KE, Bloomer, JR Bonkovsky HL, Kushner JP, Pierach CA, Pimstone NR and Desnick RJ. Recommendations for the Diagnosis and Treatment of the Acute Porphyrias. Ann Intern Med 2005; 142:439-450
  3. Deacon AC, Peters TJ, Identification of acute porphyria: evaluation of a commercial screening test for urinary porphobilinogen. Ann Clin Biochem. 1998;35:726-32